Medicare & GLP-1 FAQ: Coverage, Costs, and the Bridge Program Explained

Medicare & GLP-1 FAQ: Coverage, Costs, and the Bridge Program Explained

For the first time, Medicare is expected to cover GLP-1 medications specifically for weight loss. The Medicare GLP-1 Bridge program is scheduled to launch July 1, 2026, offering Wegovy and Zepbound at a $50/month copay to eligible beneficiaries. Whether you're asking "does Medicare cover GLP-1 for weight loss," "what is the Medicare GLP-1 Bridge program," or "who is eligible for the Medicare $50 copay for Wegovy," this FAQ covers everything Medicare enrollees need to know — from Bridge eligibility and costs to the BALANCE Model transition in 2027.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Coverage details are based on publicly available CMS guidance and may change. Verify all coverage information directly with CMS.gov or your Medicare plan. Telehealth Ally does not prescribe medications or provide insurance advice.

Does Medicare cover GLP-1 medications for weight loss in 2026?

Not yet — but this is expected to change. Historically, Medicare Part D explicitly excluded coverage for medications used solely for weight loss. That is expected to change with the Medicare GLP-1 Bridge program, which is scheduled to launch July 1, 2026.

What changed:

• CMS authorized a short-term demonstration to cover FDA-approved anti-obesity medications under Medicare
• The Bridge provides coverage for Wegovy and Zepbound at a fixed $50/month copay
• This operates outside the standard Part D benefit structure

Key dates (as scheduled):

• July 1, 2026: Bridge program expected to begin
• December 31, 2026: Bridge program scheduled to end
• January 1, 2027: BALANCE Model expected to take over under Part D

Important distinction: The Bridge covers GLP-1s approved for chronic weight management — not diabetes-indicated GLP-1s like Ozempic or Mounjaro, even though they contain the same active ingredients. For general information on GLP-1 weight loss results, see our results timeline FAQ.

What is the Medicare GLP-1 Bridge program?

The Medicare GLP-1 Bridge is a CMS short-term demonstration program planned to provide immediate access to GLP-1 weight loss medications while the longer-term BALANCE Model is finalized.

Planned program structure:

• Duration: July 1 through December 31, 2026 (6 months)
• Operates outside Part D: The Bridge would not be part of your standard Part D benefit — it would run parallel to it
• Fixed copay: $50/month for covered medications
• Covered drugs: Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide) as announced
• Administration: Would be managed by CMS, not by individual Part D plan sponsors

Why a "bridge"? CMS needed time to implement the full BALANCE Model within Part D's existing infrastructure. The Bridge is designed to ensure Medicare beneficiaries don't have to wait until 2027 to access newly covered weight loss medications.

How much will I pay for GLP-1s under the Medicare Bridge?

$50 per month — a fixed copay regardless of which covered medication you receive.

Cost context:

What the $50 copay does NOT affect:

• Your Part D deductible (Bridge is separate)
• Your Part D coverage gap ("donut hole")
• Your Part D out-of-pocket maximum ($2,000 in 2026)
• Your Part D premium

The Bridge functions as a standalone benefit, meaning Bridge spending does not interact with your regular Part D cost-sharing structure. For strategies on navigating insurance coverage for GLP-1s, see our prior authorization guide.

Who is eligible for the Medicare GLP-1 Bridge?

Eligibility requires both plan enrollment and medical criteria:

Plan requirement:

• You must be enrolled in a Medicare Part D plan — either a standalone Prescription Drug Plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD)

Medical criteria (must meet both):

• BMI threshold: Meet the FDA-approved BMI criteria for the prescribed medication (BMI ≥ 30, or BMI ≥ 27 with a qualifying comorbidity)
• Qualifying comorbidity (at least one):
  • Heart failure
  • Hypertension (high blood pressure)
  • Chronic kidney disease (CKD)
  • Pre-diabetes (HbA1c 5.7%–6.4%)
  • History of cardiovascular disease (CVD)

Who is NOT eligible:

• Medicare beneficiaries without Part D coverage
• Beneficiaries who do not meet BMI thresholds
• Beneficiaries without a qualifying comorbidity (BMI alone is not sufficient for the Bridge)
• Individuals seeking coverage for diabetes-indicated GLP-1s (Ozempic, Mounjaro) for off-label weight loss

Which GLP-1 medications does the Medicare Bridge cover?

The Bridge covers two medications, both FDA-approved for chronic weight management:

Why not Ozempic or Mounjaro? Although Ozempic contains the same molecule as Wegovy (semaglutide) and Mounjaro contains the same molecule as Zepbound (tirzepatide), their FDA-approved indications differ. The Bridge specifically covers drugs approved for weight management — not off-label use of diabetes medications.

If you have type 2 diabetes: Ozempic and Mounjaro remain covered under standard Medicare Part D for their approved diabetes indication. You would not use the Bridge for these medications.

What is the BALANCE Model and how does it replace the Bridge?

The BALANCE Model (Broad Access and Leveraging Anti-Obesity Nationally through Coverage Enhancement) is a CMS Innovation Center program that provides long-term, sustainable GLP-1 coverage through existing insurance structures.

Key details:

BALANCE timeline:

• May 2026: BALANCE begins for Medicaid
• July 2026: Bridge provides interim Medicare coverage
• January 2027: BALANCE replaces Bridge for Medicare Part D

Critical difference: Unlike the Bridge, which applies to all Part D enrollees, BALANCE requires Part D plan sponsors to opt in. This means your coverage in 2027 depends on whether your specific plan participates.

Will I need to switch Medicare plans for BALANCE?

Possibly. Because Part D plan sponsors choose whether to participate in the BALANCE Model, there is no guarantee your current plan will offer GLP-1 weight loss coverage in 2027.

What to do:

1. Contact your plan in fall 2026 to ask whether they are participating in BALANCE for 2027
2. Review the Annual Notice of Change (ANOC) — your plan must send this by September 30, 2026, detailing 2027 benefit changes
3. If your plan is not participating, use the Annual Enrollment Period (October 15 – December 7, 2026) to switch to a plan that is
4. Use Medicare.gov Plan Finder to compare BALANCE-participating plans in your area

Planning tip: Do not wait until the Bridge ends to figure this out. Start researching 2027 plan options as soon as CMS publishes the list of participating BALANCE sponsors (expected fall 2026).

Does Medicare cover Ozempic for weight loss?

No — not for weight loss. Ozempic (semaglutide) is FDA-approved exclusively for type 2 diabetes. Medicare covers Ozempic under standard Part D for its approved diabetes indication.

What this means practically:

• If you have type 2 diabetes, Medicare Part D covers Ozempic as a diabetes medication
• If you want semaglutide for weight loss, you need Wegovy — the weight-management-approved formulation — which is covered under the Bridge
• Off-label prescribing of Ozempic for weight loss is not covered under Part D or the Bridge

Common point of confusion: Ozempic and Wegovy both contain semaglutide, but they have different FDA approvals, different dosing schedules, and different coverage pathways under Medicare. Your provider can prescribe the appropriate formulation based on your diagnosis.

Does Medicare cover the oral Wegovy pill?

The oral Wegovy tablet delivers semaglutide in pill form and carries the same FDA approval for chronic weight management as injectable Wegovy. When the Bridge launches (scheduled July 1, 2026), the oral formulation is expected to be eligible since CMS covers Wegovy broadly.

However, verify before assuming coverage:

• CMS may issue formulation-specific guidance as the Bridge launches
• Pharmacy availability for oral Wegovy may vary
• Your provider and pharmacist can confirm whether the oral form is processed through the Bridge

Why this matters: Many Medicare beneficiaries prefer oral medications over injections. If oral Wegovy is confirmed under the Bridge, it removes a significant barrier to treatment adoption for patients who are needle-averse.

Source: Check CMS.gov for the most current formulary guidance as the Bridge program launch date approaches.

What about Medicare Advantage plans and GLP-1 coverage?

Medicare Advantage plans with prescription drug coverage (MA-PD) are eligible for the Bridge program — the same $50/month copay applies.

Additional MA benefits to look for:

• Nutrition counseling — Some MA plans cover registered dietitian visits as a supplemental benefit
• Fitness programs — SilverSneakers or similar gym memberships
• Weight management programs — Structured behavioral health programs for weight loss
• Enhanced pharmacy benefits — Some MA plans may offer lower copays or broader formularies beyond what standard Part D requires

Checking your MA plan:

1. Review your plan's Summary of Benefits for weight management services
2. Call the number on your member ID card to ask about GLP-1 Bridge eligibility
3. Ask whether your MA plan will participate in the BALANCE Model for 2027

Note: MA plans vary significantly by region and insurer. Two MA-PD plans in the same zip code may offer very different supplemental benefits related to weight management.

How do I enroll in the Medicare GLP-1 Bridge?

You do not enroll in the Bridge separately. Your healthcare provider initiates coverage by documenting your eligibility.

The process:

1. Schedule a visit with your primary care provider, endocrinologist, or obesity medicine specialist
2. Your provider documents:
   • Your current BMI (measured at the visit)
   • At least one qualifying comorbidity (heart failure, hypertension, CKD, pre-diabetes, or CVD history)
   • Medical appropriateness of GLP-1 therapy
3. Your provider prescribes Wegovy or Zepbound
4. The prescription is processed through the Bridge (not through your Part D plan's standard formulary)
5. You pay the $50 copay at the pharmacy

Important: The Bridge operates through CMS, not through individual Part D plan sponsors. Your pharmacist may need to process the claim differently than a standard Part D prescription. If you encounter issues, ask your pharmacist to verify Bridge processing with CMS.

What happens after the Bridge ends in December 2026?

When the Bridge concludes on December 31, 2026, GLP-1 weight loss coverage transitions to the BALANCE Model under Medicare Part D starting January 1, 2027.

Your action plan:

If you do not enroll in a BALANCE-participating plan:

• Your GLP-1 weight loss coverage will lapse on January 1, 2027
• You would need to pay out of pocket or explore manufacturer savings programs
• You could switch plans during the next Annual Enrollment Period for 2028 coverage

Do not wait until December to act. The Annual Enrollment Period closes on December 7 — three weeks before the Bridge ends. If you miss this window, you may face a gap in GLP-1 coverage.

Related Resources

• GLP-1 Cost & Insurance FAQ — Pricing, commercial coverage, and savings programs
• GLP-1 Eligibility & Access FAQ — BMI requirements, telehealth access, and who qualifies
• GLP-1 Side Effects & Safety FAQ — What to expect and when to seek help
• Provider Reviews — Compare telehealth platforms
• Provider Comparison — Side-by-side provider features and pricing